Adlai Nortye Biopharma Co., Ltd.

Lexeo Therapeutics Inc. became the 20th biopharma to launch an initial public offering in the US on 2 November when it sold 9.09 million shares at $11 each to gross $100m in its late-night public mar

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Maruho Obtains Rights To GI-301 No

Several weeks after it first planned to go public in the US, China-based Adlai Nortye Ltd. launched its initial public offering on 29 September and a concurrent private placement that together gross

Plenty of biopharmaceutical firms continue to struggle to raise fresh capital under current financial market conditions with drug developer valuations still well below what they were a few years ago a